Agenovir Overview
- Year Founded
-
2014
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Agenovir General Information
Description
Developer of novel therapeutics designed to address diseases associated with or caused by, latent or persistent viral reservoirs. The company's novel therapeutics specialize in developing a novel class of nuclease-based anti-viral therapeutics to eliminate pathogenic viral genomes, enabling healthcare providers to treat their patients suffering from devastating and persistent viral infection.
Contact Information
Website
www.agenovir.comCorporate Office
- 7000 Shoreline Court
- Suite 320
- South San Francisco, CA 94080
- United States
Corporate Office
- 7000 Shoreline Court
- Suite 320
- South San Francisco, CA 94080
- United States
Agenovir Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 09-May-2018 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 17-May-2016 | Completed | Generating Revenue | |||
| 2. Grant | 01-Jan-2016 | $149K | Completed | Generating Revenue | ||
| 1. Accelerator/Incubator | Completed | Startup |
Agenovir Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Agenovir Comparisons
Industry
Financing
Details
Agenovir Competitors (46)
One of Agenovir’s 46 competitors is Vyriad, a Venture Capital-Backed company based in Rochester, MN.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vyriad | Venture Capital-Backed | Rochester, MN | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Arisan Therapeutics | Accelerator/Incubator Backed | Carlsbad, CA | ||||
| Aro Biotherapeutics | Venture Capital-Backed | Philadelphia, PA | ||||
| CytoAgents | Venture Capital-Backed | Pittsburgh, PA |
Agenovir Patents
Agenovir Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2020154594-A2 | Compositions and methods for treatment of human papillomavirus | Inactive | 25-Jan-2019 | ||
| WO-2020154594-A3 | Compositions and methods for treatment of human papillomavirus | Inactive | 25-Jan-2019 | ||
| EP-3601568-A1 | Antiviral therapeutic | Inactive | 31-Mar-2017 | ||
| WO-2018183808-A1 | Antiviral therapeutic | Inactive | 31-Mar-2017 | ||
| WO-2018183808-A9 | Antiviral therapeutic | Inactive | 31-Mar-2017 | C12N15/1131 |
Agenovir Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Celgene | Corporation | Minority | ||
| DCVC | Venture Capital | Minority | ||
| Lightspeed Venture Partners | Venture Capital | Minority | ||
| QB3 | Accelerator/Incubator | |||
| U.S. Department of Health and Human Services | Government |
Agenovir FAQs
-
When was Agenovir founded?
Agenovir was founded in 2014.
-
Where is Agenovir headquartered?
Agenovir is headquartered in South San Francisco, CA.
-
What industry is Agenovir in?
Agenovir’s primary industry is Biotechnology.
-
Is Agenovir a private or public company?
Agenovir is a Private company.
-
What is Agenovir’s current revenue?
The current revenue for Agenovir is .
-
How much funding has Agenovir raised over time?
Agenovir has raised $10.6M.
-
Who are Agenovir’s investors?
Celgene, DCVC, Lightspeed Venture Partners, QB3, and U.S. Department of Health and Human Services have invested in Agenovir.
-
Who are Agenovir’s competitors?
Vyriad, Genetix Biotherapeutics, Arisan Therapeutics, Aro Biotherapeutics, and CytoAgents are some of the 46 competitors of Agenovir.
-
When was Agenovir acquired?
Agenovir was acquired on 09-May-2018.
-
Who acquired Agenovir?
Agenovir was acquired by Vir Biotechnology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process